Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 920-105-3 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Effects on fertility
Description of key information
Five key screening reproductive/developmental toxicity studies (OECD 422) conducted with Rosin; Rosin, hydrogenated; Rosin oligomers; and Rosin, reaction products with formaldehyde were identified.
The reproductive toxicity NOAEL for Tall Oil Rosin was determined to be 10000 ppm, the highest concentration tested (Harlan Laboratories Ltd., 2015a).
The reproductive toxicity NOAEL for Rosin, hydrogenated was determined to be 10000 ppm, the highest concentration tested (Harlan Laboratories Ltd., 2015b).
The reproductive toxicity NOEL for Rosin, reaction products with formaldehyde was determined to be 10000 ppm, the highest concentration tested (Harlan Laboratories Ltd., 2015c). No reproductive/developmental toxicity effects were observed in this study at concentrations up to 10000 ppm.
The reproductive toxicity NOAEL for Gum Rosin was determined to be 5000 ppm, based on a reduction in corpora lutea count followed by a lower number of implantation sites and lower mean litter size observed at the 10000 ppm concentration (Harlan Laboratories Ltd., 2014a).
The reproductive toxicity NOAEL for Rosin, oligomers was determined to be 3000 ppm, based on effects on pup body weights observed at the 7500 ppm and 15000 ppm concentration levels (Harlan Laboratories Ltd., 2014b).
Additionally, one key screening reproductive/developmental (OECD 421) study (Inveresk Research, 2003a) was identified conducted with Rosin. No reproductive effects were observed in this study although there was a slight reduction in litter size and slightly reduced pup weight in high dose animals (10,000 ppm in diet).
Effect on fertility: via inhalation route
- Endpoint conclusion:
- no study available
Effect on fertility: via dermal route
- Endpoint conclusion:
- no study available
Additional information
In a key combined repeated dose, reproductive/developmental OECD 422 toxicity screening study (Harlan Laboratories Ltd., 2015a), the test material (Tall oil rosin, CAS# 8050-09-7) was administered daily in dietary mixtures at concentrations of 0, 2500 ppm (males - 160 mg/Kg bw/day Pre-Pairing and 136.4 mg/Kg bw/day Post-Pairing; females - 189 mg/Kg bw/day Pre-Pairing; 182.8 mg/Kg bw/day Gestation; and 241.1 mg/K bw/day Lactation), 5000 ppm (males - 301.5 mg/Kg bw/day Pre-Pairing and 276.5mg/K bw/day Post-Pairing; females – 356.1 mg/Kg bw/day Pre-Pairing; 377.3 mg/Kg bw/day Gestation; and 572.7 mg/Kg bw/day Lactation), or 10000 ppm (males - 496.4 mg/Kg bw/day Pre-Pairing and 585.5 mg/Kg bw/day Post-Pairing; females – 612.9 mg/Kg bw/day Pre-Pairing; 772.2 mg/Kg bw/day Gestation; and 1227.9 mg/Kg bw/day Lactation) to male rats for 42 days and to female rats for 14 days prior to pairing, through the pairing and gestation periods until the F1 generation reached day 4 post partum.
Treatment resulted in slightly higher test item intake in females compared to males during the pre-pairing period. Intake remained fairly constant throughout the entire study, except during the lactation phase when, due to an increase in food consumption, intake in females was almost two-fold higher than during the preceding gestation period. In the high concentration group (10000 ppm), a reduction in food consumption resulting in body weight loss followed by reduced body weight gain, significantly reduced body weights, and significantly reduced food conversion efficiency were observed in male and female rats. A recovery was observed for food consumption in males and females and for body weight gain and food conversion efficiency in males. In females, body weight gain and food conversion efficiency recovered also initially but both values reduced again during the gestation period and remained lower than the control values during the lactation period. Body weights in both males and females, remained reduced compared to the controls during the entire study. Body weight loss in one female led to premature termination of the animal for humane reasons. In females, effects on water consumption were also noted in the 10000 ppm group; an increase was noted during the gestation period followed by a reduction during the lactation period. Due to the recovery observed during the study and because Tall Oil Rosin (CAS # 8050-09-7) is known to cause palatability problems, effects on food consumption were considered to most probably not be a sign of toxic potential but resulted from unpalatability of the test item. The lower body weights in males of the 10000 ppm group compared to concurrent control throughout the study was considered to represent impaired growth resulting from food aversion during the early treatment period. Similarly, lower body weights in females were considered to result from undernutrition at the beginning of the study. In females, however, a second drop in body weight gain and food consumption efficiency was observed during the gestation period after the recovery of food consumption. These later effects were considered to be related to potential toxicity of the test item. Reduction in body weights in both genders and reductions in body weight gain and food conversion efficiency in females at the high concentration level were considered to be adverse because they were not reversible during the course of the study.
Further, terminal examinations revealed increased liver weights in males and females in the 10000 ppm group. This effect was accompanied by an increase in alkaline phosphatase activity but no changes in the blood activity of other liver enzymes were observed and there were no histopathological lesions in this organ in any gender. For these reasons, increased liver weights were considered not to be adverse and probably a result of increased metabolism due to the exposure to foreign compound.
In the high concentration group, the number of corpora lutea was reduced, which resulted in slightly, not statistically significant lower number of implantation sites and slightly, not statistically significant lower litter size at first litter check. Mean litter size at the high concentration level remained in the range of historical control values. Slightly reduced body weight and body weight gain were observed in pups during lactation. Although the reduction was only minor and predominantly not statistically significant if compared to the current control, values at the high concentration level were lower if compared to the historical control background and therefore this observation was considered to
be related to the treatment with the test item.
Mating performance, fertility, duration of gestation, post-implantation and post-natal loss were considered not to be affected by the treatment with the test item at any concentration level. Due to adverse effects on body weight observed in females in the high concentration group, a possibility that the reduced number of corpora lutea as well as lower pup body weight were secondary to the maternal response, should be taken into consideration.
In the intermediate concentration group (5000 ppm), a slight reduction in food consumption was observed in both genders at the beginning of the treatment. In males, this resulted in slight reductions in body weight gain and food conversion efficiency at the beginning of the treatment and slightly, not statistically significant, lower body weights during the entire study. In females, body weight gain and food conversion efficiency were also slightly reduced at the beginning of the study and recovered thereafter whereas body weights were not changed compared to the control values during the entire study. Food conversion efficiency reduced again during the gestation period but recovered and was higher than the control value during the lactation period. Water consumption was slightly and reversibly increased in females of this group. Due to reversibility, effects on food consumption, body weights and water consumption in the intermediate concentration group were considered not to be adverse. Although food conversion efficiency was significantly lower in this group again during the gestation period, it recovered during the lactation period and did not correlate with reduced body weight gain or reduced body weights and therefore this effect was also considered not to be adverse.
In the 5000 ppm group, increased liver weights were observed in males and females but without histopathological lesions or changes in related clinical biochemistry parameters and therefore considered not to be adverse. No effects on reproductive or developmental parameters were observed in animals in the 5000 ppm group. In the low concentration group (2500 ppm), no signs of general toxicity in males or females as well as no effects on reproduction or development were observed.
Based on these observations, the NOEL (No Observed Effect Level) was established at the concentration level of 2500 ppm and the NOAEL (No Observed Adverse Effect Level) was established at 5000 ppm for general toxicity. For reproductive and developmental toxicity, the NOEL was established at 5000 ppm whereas the NOAEL was established at the concentration level of 10000 ppm, the highest concentration tested in the study.
In a key combined repeated dose, reproductive/developmental toxicity study (OECD 422), the test material (Rosin, hydrogenated; CAS# 65997-06-0) was continuously administered in feed to rats (12/sex/concentration) at concentrations of 0, 1000, 3000, and 10000 ppm. The test material was administered to male rats for 43 days and to female rats for 14 days prior to pairing, through the pairing and gestation periods until the F1 generation reached day 4 post partum (Harlan Laboratories Ltd., 2015b).
Test material-related effects were observed in males and females in group 4 (10000 ppm) whereas in groups 2 (1000 ppm) and 3 (3000 ppm) no signs of general toxicity were noted in either gender. Microscopic examination of selected organs revealed pathological changes in groups 2, 3 and 4.
In group 4, reduction in food consumption and food conversion efficiency resulting in body weight loss, reduced body weight gain and significantly reduced body weights were observed in both genders. The effect on food consumption was considered to most probably not be a sign of toxic potential but to result from unpalatability of the test item. Food consumption recovered during the study and therefore the effect was considered not to be adverse. Although body
weight gain increased and was similar to the control values after the initial reduction, body weights remained lower than the control group values during the entire study period in males and females. The persistent reduction in body weights was considered to be adverse.
An increase in activities of alanine aminotransferase and alkaline phosphatase were measured in the blood of males in group 4. This finding was considered to be indicative of liver cell injury and therefore adverse.
Increased liver weights were recorded at necropsy in males in group 4. This finding was correlated histologically with hepatocellular hypertrophy. Increased liver weights and hepatocellular hypertrophy are suggestive of an adaptative response to mixed function oxidase induction. In the pituitary, enlarged vacuolated cells were observed. This change may reflect hypertrophy of thyroid-stimulating hormone-producing cells (thyrotrophs), a common finding following administration of liver enzyme inducers where the underlying mechanism is considered to be increased hepatic clearance of thyroid hormones followed by a compensatory increase in the pituitary secretion of TSH. Further, minimal hypertrophy of zona glomerulosa was observed during microscopic examinations in the adrenal glands of males in groups 3 and 4 and of females in groups 2, 3 and 4. The pathogenesis of this change is uncertain. The zona glomerulosa is the site of synthesis of aldosterone a mineralocorticoid which is mainly involved in the control of salt and water balance in the body. Secretion of aldosterone is controlled through the renin-angiotensin system and hypertrophy of the zona glomerulosa is generally considered to be an adaptative process following stimulation of this system.
There were no test item related microscopic findings in the reproductive organs, including the qualitative examination of the stages of spermatogenesis in the testes (no test item related abnormalities in the integrity of the various cell types present within the different stages of the sperm cycle) and the evaluation of the uterus or evaluation of follicles and corpora lutea in the ovaries. There were no test item related microscopic findings in the males or females suspected of reduced fertility.
A reduction in corpora lutea count was observed in females ingroup 4 during the macroscopic evaluation at necropsy whereas histopathological evaluation of follicles and corpora lutea in the ovaries did not reveal any test item-related effect. Because no significant changes in the number of implantation sites or litter size were observed during the study, the reduction in corpora lutea count was considered not to be adverse. Further, the effect on corpora lutea count may possibly be secondary to the toxic effects in females observed in this group. Remaining reproduction parameters: mating performance, fertility, duration of gestation, post implantation and postnatal loss were not affected by the treatment with the test item at any dose level.
With exception for a slight retardation in pup body weights in the presence of adversely reduced food consumption and body weight in females in group 4, no effects on development were observed during the study. The changes in pup body weights were only minor (not statistically significant if compared to the control group), and values in the high-dose group were close to the normal background range in this rat strain. The reduction in pup body weights represents a delayed growth rather than a developmental disturbance. This effect is commonly seen in the presence of maternal toxicity manifested as decreased food consumption associated with reduced body weights and it is considered to be secondary to the maternal toxicity. For these reasons, effects on pup body weights were considered not to be adverse and likely to be a secondary response.
Due to the histopathological changes in adrenal glands, no NOEL (No Observed Adverse Effect Level) for general toxicity was established for females whereas for males it was at the dose level of 1000 ppm. The NOAEL (No Observed Adverse Effect Level) was established at 3000 ppm. For reproduction and developmental toxicity, the NOEL was established at the dose level of 3000 ppm whereas the NOAEL was at 10000 ppm, the highest dose level used in the study.
In a key reproductive/developmental toxicity study (OECD 422), the toxicological effects on rats resulting from continuous dietary oral administration of the test material (Rosin, reaction product with formaldehyde, CAS # 91081-53-7) were evaluated (Harlan Laboratories Ltd., 2015c). The test material was administered daily in dietary mixtures at concentrations of: 0, 1000, 3000 and 10000 ppm to male rats for 43 days and to female rats for 14 days prior to pairing, through the pairing and gestation periods until the F1 generation reached day 4 post-partum.No unscheduled deaths were recorded during the study period. No clinical signs were recorded. Slight reductions in food consumption and water consumption and low body weight and body weight gain was recorded in males and females of group 4. The effect was likely due to the reduced palatability of the diet at the higher concentration. Slightly low body weights and reduced water consumption were noted in males of groups 2 and 3. Minimal hypertrophy of the zona glomerulosa were observed in the adrenal glands in males and females of groups 3 and 4. The pathogenesis was considered to be an adaptive process following stimulation of this system. Increased liver weights were recorded at necropsy in males and females of group 4 and these findings are suggestive of an adaptive response to mixed function oxidase induction and considered not to be adverse.
The sperm motility, morphology and sperm count, estrus cycle, mating performance, fertility, duration of gestation, corpora lutea count, implantation rate, post-implantation and postnatal loss and litter size were not affected by treatment with the test material at any concentration. There were no test material-related findings in pups noted during the first litter check, the first 4 days post-partum or during the necropsy.Based on the result of the study, the NOAEL (No Observed Adverse Effect Level) for general toxicity was established at a concentration of 10000 ppm and the NOEL (No Observed Effect Level) was established at a concentration of 1000 ppm.The NOAEL and NOEL for reproduction/ developmental toxicity were established at a concentration of 10000 ppm, the highest concentration used in the study.
In another key combined repeated dose, reproductive/developmental (OECD 422) toxicity study (Harlan Laboratories Ltd., 2014a), Gum Rosin was administered to rats (12/sex/dose) in dietary mixtures at concentrations of 0, 2500, 5000, and 10000 ppm for a period of 50 days for male rats and to female rats for 14 days prior to pairing, through the pairing and gestation periods until the F1 generation reached day 4 post partum (at least 36 days, up to 53 days).The treatment with the test item did not lead to any premature mortalities and had no effects on behaviour, reflexes, grip strength, locomotor activity, and hematology parameters. Mating performance, fertility index, duration of gestation, and post-implantation loss were not affected by the treatment with the test item at any dose level. No abnormal findings were recorded at the first litter check and at necropsy of the pups. No effects of the treatment on sex ratio and righting reflex were observed.
In the high dose group (10000 ppm), in both sexes, significantly lower food consumption was recorded during the first treatment week. From treatment week 2 until the end of the treatment period the food consumption was slightly decreased in males, but still significantly decreased in females when compared to the control group. The lower food consumption led to a transient lower body weight gain and lower body weights until the end of the study in both sexes. Except for ruffled fur in one female from the last day of gestation to the end of the lactation period, no clinical signs were observed. The water consumption was significantly reduced during the lactation period which was possibly due to the lower number of pups and therefore lower milk production in this group.
Increased activity of alkaline phosphatase in males and increased bilirubin concentration in both sexes did not correlate with other findings and were therefore not considered adverse. Decreased absolute and relative thymus weights in females recorded at necropsy correlated with decreased lymphocytes in the cortex of the thymus. This finding was considered to be stress-related and likely not a direct effect of the test item.
The mean numbers of corpora lutea and implantations per dam as well as the mean litter size at the first litter check were decreased. The postnatal loss was slightly increased. In addition, the male and female pup weights were significantly lower on day 1 and 4 post partum when compared to the controls. Pups from one litter were cold to the touch on days 3 and 4 post partum. The effects on reproduction and pups were considered likely to be secondary to the effects of the treatment on food consumption and body weight development of the dams.
In the intermediate dose group (5000 ppm), lower food consumption was recorded in males and females during the first treatment week. From treatment week 2 onwards the food consumption was similar to the control group in males, but still decreased in females. The lower food consumption led to a transient lower body weight gain in males during the pre-paring period. However, decreased body weights compared to the concurrent controls were recorded during the entire treatment period in females. No clinical signs were observed at this dose level. The water consumption of females was slightly reduced during the lactation period.
In the low dose group (2500 ppm), a transiently slightly lower body weight gain was recorded during the pre-pairing period in males. Afterwards the body weight development at this dose level was similar to the controls.
The creatinine concentration was increased at all dose levels in males. An increase of creatinine is usually a sign for kidney damage. However, no histopathological findings were recorded in the kidneys. Therefore, the increase of the creatinine was not considered to be an adverse effect. Minimal hypertrophy/vacuolation of the zona glomerulosa was observed in the adrenal glands of males from the 2500 ppm group and in females from the 5000 ppm group with dose related-incidence. The pathogenesis of this change is uncertain. The zona glomerulosa is the site of synthesis of aldosterone which is mainly involved in the control of salt and water balance in the body. Secretion of aldosterone is controlled through the renin-angiotensin system and hypertrophy of the zona glomerulosa is generally considered to be an adaptative process following stimulation of this system. Therefore, this change was not considered to be an adverse effect.
Based on the results of this study, a NOEL (No Observed Effect Level) for general toxicity could not be established due to effects on body weights at all dose levels in females during the lactation period. The NOAEL (No Observed Adverse Effect Level) for general toxicity was established at the dose level of 2500 ppm. The NOEL and the NOAEL for reproduction/developmental toxicity were established at 5000 ppm.
In another key combined repeated dose, reproductive/developmental toxicity study (OECD 422), the test material (Rosin, oligomers; CAS # 65997-05-9) was administered to rats (12/sex/concentration) in dietary mixtures at concentrations of 0, 3000, 7500 and 15000 ppm (Harlan Laboratories Ltd., 2014b). The test material was continuously administered to male rats for 43 days and to female rats for 14 days prior to pairing, through the pairing and gestation periods until the F1 generation reached day 4 post partum (up to 55 days). Oral exposure to the test material had no effects on behavior, reflexes, grip strength, locomotor activity, and hematology parameters. No clinical signs of toxicological relevance were observed and mating performance, fertility index, and duration of gestation were not affected by the treatment at any concentration level. No test material related abnormal findings were recorded at the first litter check and at necropsy of the pups. No effects of the treatment on sex ratio and righting reflex were observe through the study period.
One female rat in the high concentration group was observed in a moribund condition and was sacrificed on treatment day 13. The moribund condition was considered to be caused by the treatment with the test item. In Group 4 females, significantly lower food consumption was recorded during the entire treatment period which led to a lower body weight gain and body weights through the entire treatment period. In Group 4 males, the food consumption was reduced during the pre-pairing period which led to a lower body weight gain during the pre-pairing and pairing period. The body weights of the males were decreased during the entire treatment period. The water consumption of females was decreased during the entire treatment period, but was not altered in males.
Increased activity albumin concentration in both sexes, increased bilirubin concentration in females and increased triglyceride concentration in females were observed in the high concentration animals. While these effects were considered test material-related, they did not clearly correlate with other findings and were therefore not considered adverse. Increased liver weights were observed in both sexes were correlated microscopically with minimal centrilobular hepatocellular hypertrophy. These findings are suggestive of an adaptative response to mixed function oxidase induction. Decreased adrenal weights were also observed in both sexes in the high concentration group animals. Minimal hypertrophy of the zona glomerulosa was observed in the adrenal glands of female rats. The pathogenesis of this change is uncertain. The zona glomerulosa is the site of synthesis of aldosterone, a mineralocorticoid which is mainly involved in the control of salt and water balance in the body. Secretion of aldosterone is controlled through the renin-angiotensin system and hypertrophy of the zona glomerulosa is generally considered to be an adaptative process following stimulation of this system.
The mean numbers of corpora lutea and implantations per dam were decreased and the total number of post implantation losses was significantly higher in Group 4 females than in the control group. This led to a lower mean number of living pups per litter at the first litter check. In addition, the body weight gain of male and female pups was significantly lower on day 4 post partum when compared to the controls. These observations could be secondary to lower maternal food consumption and body weight gain in this group.
In the intermediate concentration Group (Group 3), decreased food consumption was recorded during the first four treatment days in females which led to a lower body weight gain during the pre-pairing period and decreased body weights through the entire treatment period. In males, the food consumption was slightly reduced during the pre-pairing period which led to a lower body weight gain during the pre-pairing period and lower body weights until the end of the study. Increased liver weights were observed in both sexes correlated microscopically with minimal centrilobular hepatocellular hypertrophy in males. Minimal hypertrophy of the zona glomerulosa in the adrenal glands of females and decreased adrenal weights in males were also observed. Significant lower mean body weight gain was recorded on day 4 post partum in pups of both sexes.
In Group 2 (3000 ppm), slightly lower body weight gain was observed during the first four days of treatment at the beginning of the pre-pairing period and slightly increased liver weights in males were observed. No other test material-related effects were recorded.
Based on the results of this study, the NOAEL (No Observed Adverse Effect Level) for systemic toxicity in male rats was established at 7500 ppm, based on statistically significant body weight and body weight gain effects observed at the 15000 ppm concentration level. The systemic toxicity NOAEL for female rats was determined to be 3000 ppm, based on effects on body weight and body weight gain in females exposed to the test material at 7500 and 15000 ppm. The NOEL and the NOAEL for reproductive/developmental toxicity was determined to be 3000 ppm.
In a reproductive and developmental toxicity screening study conducted according to OECD Guideline 421 (Inveresk Research, 2003a), male and female Sprague Dawley rats were exposed to 0, 1000, 3000 or 10,000 ppm Gum Rosin (Rosin) in the diet during pre-mating, mating, gestation and lactation for a total of 30 exposure days for males and 41-45 exposure days for females. At 10,000 ppm in the diet (equivalent to 786 mg/kg bw/f for males and 869 mg/kg bw/d for females), there were no test material-related effects on mating performance, male and female fertility indices, or length of gestation and no gross or microscopic effects on reproductive organs of either sex. The mean number of implant sites per pregnancy was slightly reduced resulting in a slight reduction in litter size. Mean litter and pup weights were also slightly reduced. The effect on implantation, litter size and fetal weight may be secondary to the effects on decreased food intake and subsequent lower weight gain observed in the adult females. A NOAEL of 3000 ppm, equivalent to 248 (males) to 309 (females) mg/kg bw/d was derived from this study.
In guideline repeat exposure studies (OECD 408), there were no gross or microscopic changes in reproductive organs of male or female rats exposed to Rosin; Rosin, hydrogenated; or Rosin, reaction products with formaldehyde for a period of 90 days.
Effects on developmental toxicity
Description of key information
One key pre-natal developmental toxicity study (OECD 414) was identified conducted with Rosin (Envigo Research Limited, 2017c). In-utero survival of the developing conceptus was unaffected by maternal exposure at 7500 ppm, although reduced foetal and placental weights indicated an adverse effect on foetal growth. The absence of any structural defects indicated that development per se was unaffected at this dietary exposure level. The ‘No Observed Adverse Effect Level’ (NOAEL) for foetal developmental toxicity was considered to be 5000 ppm (equivalent to a mean achieved dosage of 387.2 mg/kg bw/day).
Five key screening reproductive/developmental toxicity studies (OECD 422) conducted with Rosin; Rosin, hydrogenated; Rosin oligomers; and Rosin, reaction products with formaldehyde were identified.
The developmental toxicity NOEL for Rosin was established at 5000 ppm, whereas the NOAEL was established at the concentration level of 10000 ppm, the highest concentration tested in the study (Harlan Laboratories Ltd., 2015a).
The developmental toxicity NOEL for Rosin, hydrogenated was established at the dose level of 3000 ppm whereas the NOAEL was at 10000 ppm, the highest dose level used in the study (Harlan Laboratories Ltd., 2015b).
The developmental toxicity NOEL and NOAEL for Rosin, reaction products with formaldehyde were established at a concentration of 10000 ppm, the highest concentration used in the study (Harlan Laboratories Ltd., 2015c).
The developmental toxicity NOEL and NOAEL for Gum Rosin were established at 5000 ppm, based on mortality and body weight effects observed at the 10000 ppm concentration level (Harlan Laboratories Ltd., 2014a).
The developmental toxicity NOEL and NOAEL for Rosin, oligomers were determined to be 3000 ppm, based on effects on pup body weight at concentrations of 7500 and 15000 ppm (Harlan Laboratories Ltd., 2014b).
One key screening reproductive/developmental (OECD 421) was identified conducted with Rosin (Inveresk Research, 2003a). No developmental effects were observed in this study although there was a slight reduction in litter size in high dose dams (10,000 ppm in diet).
Link to relevant study records
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2015-07-30 to 2016-02-23
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Justification for type of information:
- A discussion and report on the read across strategy is given as an attachment in Section 13.
- Reason / purpose for cross-reference:
- read-across: supporting information
- Reason / purpose for cross-reference:
- reference to same study
- Remarks:
- Section 7.5.1.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Deviations:
- yes
- Remarks:
- deviations had no adverse impact on the scientific purpose of the study.
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Remarks:
- Crl:CD (SD) IGS BR strain
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River (UK) Limited,Margate, Kent.
- Age at study initiation: Not specified
- Weight at study initiation: 181 to 302g.
- Fasting period before study: Not specified
- Housing: The animals were housed individually in solid-floor polypropylene cages with stainless steel mesh lids furnished with softwood flakes (Datesand Ltd., Cheshire, UK).
- Diet (e.g. ad libitum): Ground diet (Rodent PMI 5002 (Certified), BCM IPS Limited, London, UK) was used ad libitum
- Water (e.g. ad libitum): Mains drinking water was supplied ad libitum from polycarbonate bottles attached to the cage
- Acclimation period: Not specified
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 3 ºC
- Humidity (%): 50 ± 20%
- Air changes (per hr): at least fifteen air changes per hour
- Photoperiod (hrs dark / hrs light): low intensity fluorescent lighting was controlled to give twelve hours continuous light and twelvehours darkness
IN-LIFE DATES: From: 2015-09-25 To: 2015-10-14 - Route of administration:
- oral: feed
- Vehicle:
- unchanged (no vehicle)
- Details on exposure:
- DIET PREPARATION
- Rate of preparation of diet (frequency): Dietary admixtures were prepared once and stored at room temperature
- Mixing appropriate amounts with (Type of food): A known amount of test item was mixed with a small amount of basal laboratory diet in a Robot Coupe Blixer 4 mixer until homogeneous. This pre-mix was then added to a larger amount of basal laboratory diet and mixed for a further sixty minutes at a constant speed, setting 1 in a Hobart H800 mixer.
- Storage temperature of food: stored at room temperature - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The stability and homogeneity of the dietary admixtures were determined by Envigo Research Limited (Shardlow, UK, Analytical Services). Dietary admixtures were prepared once and stored at room temperature. Samples were taken and analyzed for
concentration of Rosin CAS 8050-09-7 at Envigo Research Limited (Shardlow, UK, Analytical Services). The results indicate that the prepared formulations were within 101% to 110% of the nominal concentration confirming the suitability and accuracy of the formulation procedure. - Details on mating procedure:
- A total of ninety-six time-mated female Sprague-Dawley Crl:CD(SD) IGS BR strain rats were obtained from Charles River (UK) Limited,Margate, Kent. Animals were delivered in two batches containing females prior to Day 3 of gestation. The day that positive evidence of mating was observed was designated Day 0 of gestation.
- Duration of treatment / exposure:
- From gestation day 3 to 19.
- Frequency of treatment:
- Continuously administered in the diet
- Duration of test:
- From gestation day 3 to 19.
- Dose / conc.:
- 0 ppm
- Remarks:
- Control
- Dose / conc.:
- 2 500 ppm
- Remarks:
- Low (equivalent to 199.3 mg/Kg bw/day)
- Dose / conc.:
- 5 000 ppm
- Remarks:
- Intermediate (equivalent to 387.2 mg/Kg bw/day)
- Dose / conc.:
- 7 500 ppm
- Remarks:
- High (equivalent to 561.1 mg/Kg bw/day)
- No. of animals per sex per dose:
- 24/concentration
- Control animals:
- yes, concurrent no treatment
- Details on study design:
- - Dose selection rationale: The dose levels were chosen based on previous toxicity data (Harlan Laboratories Ltd., Study Number D80926: Tall Oil Rosin-CAS No. 8050-09-7: Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test in the Han Wistar Rat).
- Rationale for animal assignment (if not random): The animals were randomly allocated to treatment groups using a randomization procedure based on stratified body weight to ensure similarity between the treatment groups. The animals were uniquely identified within the study by an ear punching system routinely used in these laboratories. - Maternal examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Daily
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Following arrival, all animals were examined for overt signs of toxicity, ill-health or behavioural changes once daily during the gestation period.
BODY WEIGHT: Yes
- Time schedule for examinations: Individual body weights were recorded on gestation days 3, 4, 5, 8, 11, 14, and 17. Body weights were also recorded for animals at terminal kill (Day 20).
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study): Yes
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
Food consumption was recorded for each individual animal on gestation days 3, 5, 8, 11, 14, 17 and 20.
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): Yes
- Time schedule for examinations: Water intake was observed daily by visual inspection of the water bottles for any overt changes.
POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day # 20
All animals were killed by carbon dioxide asphyxiation followed by cervical dislocation on Day 20 of gestation. All animals were subjected to a full external and internal examination and any macroscopic abnormalities were recorded. - Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: Yes
- Number of late resorptions: Yes
- Other:
i) Number, position and type of intrauterine implantation
ii) Foetal sex
iii) External foetal appearance
iv) Foetal weight
v) Placental weight - Fetal examinations:
- - External examinations: Yes: [all per litter ]
- Soft tissue examinations: Yes: [all per litter]
- Skeletal examinations: Yes: [all per litter]
- Head examinations: Yes: [all per litter] - Statistics:
- The following parameters wereanalysed statistically, where appropriate, using the test methods outlined below:
Female body weight change, food consumption and gravid uterus weight: Shapiro Wilk normality test and Bartlett’s test for homogeneity of variance and one way analysis of variance, followed by Dunnett’s multiple comparison test or, if unequal variances were observed, on alternative multiple comparison test. All caesarean necropsy parameters and foetalparameters: Kruskal-Wallis non-parametric analysis of variance; and a subsequent pairwise analysis of control values against treated values using the Mann-Whitney ‘U’ test, where significance was seen. Foetal evaluation parameters, including skeletal or visceral findings: Kruskal-Wallis nonparametric analysis of variance and Mann-Whitney ‘U’ test.
Probability values (p) are presented as follows:
p<0.001 ***
p<0.01 **
p<0.05 *
p≥0.05 (not significant) - Indices:
- 1) Pre and Post Implantation Loss: Percentage pre-implantation loss was calculated as:
((Number of Corpora Lutea - Number of Implantations)/(Number of Corpora Lutea)) x 100
2) Percentage post-implantation loss was calculated as:
((Number of Implantations - Number of live Foetuses)/(Number of Implantations)) x 100
3) Sex Ration: Sex ratio was calculated as:
% male foetuses (sex ratio) = (Number of Male Foetuses/Total Number of Foetuses) x 100 - Clinical signs:
- no effects observed
- Description (incidence and severity):
- No clinical signs of toxicity were detected.
One female in the 7500 ppm dietary group had generalised scab formation between gestation days 1 and 6. This was present before the start of test item administration and therefore unrelated to treatment. - Mortality:
- no mortality observed
- Description (incidence):
- There were no unscheduled deaths.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Females fed diet containing 7500 or 5000 ppm showed a reduction in body weight gain between gestation days 3, 4, 5, 8, 14 and 17. Although statistical significance was not achieved, actual body weight losses were evident between gestation days 3 and 4. Consequently, overall body weight gains were statistically significantly reduced (p<0.05-0.001) in females fed diet with 7500 ppm from gestation day 8 and in females fed diet with 5000 ppm from gestation day 17 (p<0.05). Body weight gain when adjusted for gravid uterus weight was also statistically significantly reduced (p<0.05) in females fed diet containing 7500 ppm. No adverse effects were detectedin body weight development for females fed diet containing 2500 ppm.
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- Females fed diet containing 7500 ppm showed a statistically significant reduction (p<0.01-0.001) in food consumption between gestation days 3 and 11. Recovery was evident thereafter. Females fed diet containing 5000 ppm showed a statistically significant reduction (p<0.05) in food consumption between gestation days 5 and 8. Food consumption for these females during the remaining periods were comparable to controls. No adverse effects were detected in food consumption for females fed diet containing 2500 ppm.
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Description (incidence and severity):
- Daily visual inspection of water bottles did not reveal any overt intergroup differences.
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- No abnormalities were detected during the macroscopic examination of the pregnant females at termination on gestation day 20.
- Number of abortions:
- no effects observed
- Pre- and post-implantation loss:
- no effects observed
- Description (incidence and severity):
- There was no effect of maternal exposure to 2500, 5000 or 7500 ppm of the test item on litter data, as assessed by numbers of implantations, in-uteroo ffspring survival (as assessed by the mean numbers of early or late resorptions), live litter size, sex ratio and pre and post implantation losses.
- Total litter losses by resorption:
- no effects observed
- Description (incidence and severity):
- There was no effect of maternal exposure to 2500, 5000 or 7500 ppm of the test item on litter data, as assessed by numbers of implantations, in-utero offspring survival (as assessed by the mean numbers of early or late resorptions), live litter size, sex ratio and pre and post implantation losses.
- Early or late resorptions:
- no effects observed
- Description (incidence and severity):
- There was no effect of maternal exposure to 2500, 5000 or 7500 ppm of the test item on litter data, as assessed by numbers of implantations, in-utero offspring survival (as assessed by the mean numbers of early or late resorptions), live litter size, sex ratio and pre and post implantation losses.
- Description (incidence and severity):
- Migrated Data from removed field(s)
Field "Effects on pregnancy duration" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsMaternalAnimals.MaternalDevelopmentalToxicity.EffectsOnPregnancyDuration): no effects observed - Description (incidence and severity):
- At the 7500 ppm dietary exposure level, mean foetal weights for both sexes and placental weights were statistically significantly reduced (p<0.01 and p<0.05 respectively). No similar effects on foetal or placental weights were detected at the 5000 or 2500 ppm dietary exposure levels.
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 2 500 ppm
- Based on:
- test mat.
- Basis for effect level:
- body weight and weight gain
- other: Systemic Toxicity
- Remarks on result:
- other: equivalent to a mean achieved dosage of 199.3 mg/kg bw/day
- Key result
- Abnormalities:
- effects observed, treatment-related
- Localisation:
- placenta
- Description (incidence and severity):
- At the 7500 ppm dietary exposure level, placental weights were statistically significantly reduced ( p<0.05).
- Fetal body weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- At the 7500 ppm dietary exposure level, mean foetal weights for both sexes were statistically significantly reduced (p<0.01 and p<0.05 respectively). No similar effects on foetal weights were detected at the 5000 or 2500 ppm dietary exposure levels.
- Reduction in number of live offspring:
- no effects observed
- Changes in sex ratio:
- no effects observed
- Changes in litter size and weights:
- no effects observed
- External malformations:
- no effects observed
- Description (incidence and severity):
- Neither the type, incidence nor the distribution of findings observed during external examination of the foetuses at necropsy on gestation day 20 and subsequent detailed visceral and skeletal examination indicated any adverse effect of maternal dietary exposure to the test item on foetal development.
- Skeletal malformations:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Neither the type, incidence nor the distribution of findings observed during external examination of the foetuses at necropsy on gestation day 20 and subsequent detailed visceral and skeletal examination indicated any adverse effect of maternal dietary exposure to the test item on foetal development.
A statistically significant reduction in the number of foetuses/litters showing incomplete ossification of the squamosal bone of the skull was evident at 7500 and 5000 ppm. There was also a statistically significant reduction in the number of foetuses/litters showing no ossification of the hyoid in the skull at 2500 and 7500 ppm and a statistically significant increase in the number of foetuses/litters showing dumb-bell shaped thoracic centrum at 5000 ppm. The group means of each of these skeletal findings were all within historical control ranges and in the absence of trueexposure related responses, the intergroup differences were considered to reflect normal biological variation. A statistically significant increase in the number of foetuses/litters showing ossification centre associated with 1st lumbar vertebra was evident at 2500, 5000 and 7500 ppm. The foetal/litter incidence of this finding was: 1/1; 13/8; 24/13; and 56/18 in the 0, 2500, 5000 and 7500 ppm groups respectively. The historical control range for this parameter was 4.9% to 13.7% and although group mean values at 5000 and 7500 ppm were above the historical control range, the control group mean incidence was significantly below the historical control range, with an atypically
lower value than expected for this parameter. This variation is indicative of precocious ossification, however it was seen in isolation of other developmental changes such as increased mean foetal weight. No other skeletal structures showed evidence of precocious ossification and there was evidence of only one skeletal structure showing delayed ossification (incomplete ossification of the squamosal bone of the skull). Consequently, this was considered to be an isolated finding which was not regarded as evidence of adverse developmental toxicity (Carney and Kimmel, 2007). - Visceral malformations:
- no effects observed
- Description (incidence and severity):
- Neither the type, incidence nor the distribution of findings observed during external examination of the foetuses at necropsy on gestation day 20 and subsequent detailed visceral and skeletal examination indicated any adverse effect of maternal dietary exposure to the test item on foetal development.
- Other effects:
- effects observed, non-treatment-related
- Description (incidence and severity):
- One female at the lowest dietary exposure level (2500 ppm) had conjoined twin foetuses. In the absence of a similar effect at the higherexposure levels this finding was considered incidental and unrelated to treatment.
At the highest dietary exposure level (7500 ppm), a statistically significant reduction (p<0.05) in the foetal incidence of non-uniform patterning of the rugae was observed. A reduction in this parameter is considered not to be an adverse developmental effect. - Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 5 000 ppm
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- fetal/pup body weight changes
- Remarks on result:
- other: equivalent to a mean achieved dosage of 387.2 mg/kg bw/day
- Key result
- Abnormalities:
- no effects observed
- Key result
- Developmental effects observed:
- yes
- Lowest effective dose / conc.:
- 5 000 ppm
- Treatment related:
- yes
- Relation to maternal toxicity:
- developmental effects as a secondary non-specific consequence of maternal toxicity effects
- Dose response relationship:
- yes
- Relevant for humans:
- not specified
- Conclusions:
- The oral administration of Rosin CAS 8050-09-7 to pregnant rats by continuous dietary exposure during gestation days 3 to 19, at concentrations of 2500, 5000 or 7500 ppm was associated with lower maternal body weight gain during gestation and an initial effect on food consumption at 7500 ppm and lower maternal body weight gain at 5000 ppm. No similar effects were apparent at 2500 ppm (equivalent to a mean achieved dosage of 199.3 mg/kg bw/day) which was considered to represent the No Observed Adverse Effect Level (NOAEL) for the pregnant female.
In-utero survival of the developing conceptus was unaffected by maternal exposure at 7500 ppm, although reduced foetal and placental weights indicated an adverse effect on foetal growth. The absence of any structural defects indicated that development per se was unaffected at this dietary exposure level. At 5000 or 2500 ppm no adverse treatment-related changes were detected in the offspring parameters measured or on embryofoetal development. The ‘No Observed Adverse Effect Level’ (NOAEL) for foetal developmental toxicity was therefore considered to be 5000 ppm (equivalent to a mean achieved dosage of 387.2 mg/kg bw/day). - Executive summary:
In a key pre-natal developmental toxicity study, the test material (Rosin, CAS# 8050-09-7) was administered by continuous dietary admixture to three groups each composed of twenty-four time mated Sprague-Dawley Crl:CD®(SD) IGS BR strain rats, between gestation days 3 and 19 (inclusive) at dietary concentrations of 2500, 5000, or 7500 ppm (equivalent to mean achieved dosages of 199.3, 387.2 or 561.1 mg/kg bw/day respectively). A further group of twenty-four time mated females was fed basal laboratory diet to serve as a control.
Clinical signs, body weight change, food and water consumptions were monitored during the study. All females were terminated on gestation day 20 and subjected to gross necropsy including examination of the uterine contents. The number of corpora lutea, number, position and type of implantation, placental weights, foetal weight, sex and external and internal macroscopic appearance were recorded. Half of the pups from each litter were examined for detailed skeletal development and the remainder were subjected to detailed visceral examination.
The oral administration of the test material to pregnant rats by continuous dietary exposure was associated with lower maternal body weight gain during gestation and an initial effect on food consumption at 7500 ppm and lower maternal body weight gain at 5000 ppm. No similar effects were apparent at 2500 ppm (equivalent to a mean achieved dosage of 199.3 mg/kg bw/day) which was considered to represent the No Observed Adverse Effect Level (NOAEL) for the pregnant female.
In-utero survival of the developing conceptus was unaffected by maternal exposure at 7500 ppm, although reduced foetal and placental weights indicated an adverse effect on foetal growth. The absence of any structural defects indicated that development per se was unaffected at this dietary exposure level. At 5000 or 2500 ppm no adverse treatment-related changes were detected in the offspring parameters measured or on embryofoetal development. The ‘No Observed Adverse Effect Level’ (NOAEL) for foetal developmental toxicity was therefore considered to be 5000 ppm (equivalent to a mean achieved dosage of 387.2 mg/kg bw/day).
Reference
Table 2. Group Mean Body Weight Change Values |
||||||||
Dietary Concentration (ppm) |
|
Cumulative Body Weight Change (g) from Day 3 of Gestation |
||||||
4 |
5 |
8 |
11 |
14 |
17 |
20 |
||
0 (Control) |
Mean |
2.4 |
4.7 |
22.3 |
43.0 |
63.3 |
92.4 |
140.0 |
SD |
5.4 |
8.5 |
8.5 |
10.8 |
9.8 |
11.6 |
15.9 |
|
n |
23 |
23 |
23 |
23 |
23 |
23 |
23 |
|
|
||||||||
2500 |
Mean |
1.1 |
5.3 |
20.6 |
42.4 |
63.2 |
88.8 |
134.7 |
SD |
6.1 |
5.5 |
8.1 |
8.3 |
11.1 |
12.6 |
13.9 |
|
n |
23 |
23 |
23 |
23 |
23 |
23 |
23 |
|
|
||||||||
5000 |
Mean |
-0.8 |
2.6 |
17.3 |
37.2 |
57.5 |
83.0* |
126.3* |
SD |
7.6 |
7.3 |
10.7 |
10.5 |
9.0 |
13.3 |
21.3 |
|
n |
24 |
24 |
24 |
24 |
24 |
24 |
24 |
|
|
||||||||
7500 |
Mean |
-1.3 |
0.1 |
14.5* |
33.1** |
51.3** |
76.5*** |
122.8** |
SD |
7.7 |
8.9 |
10.1 |
10.5 |
14.2 |
15.5 |
19.3 |
|
n |
24 |
24 |
24 |
24 |
24 |
24 |
24 |
Table 3. Group Mean Food Consumption Values |
|||||||
Dietary Concentration (ppm) |
|
Food Consumption (g/rat/day) between Days of Gestation |
|||||
3-5 |
5-8 |
8-11 |
11-14 |
14-17 |
17-20 |
||
0 (Control) |
Mean |
15.9 |
22.3 |
24.7 |
24.3 |
27.1 |
27.2 |
SD |
2.5 |
2.6 |
2.4 |
2.7 |
1.8 |
2.2 |
|
n |
23 |
23 |
23 |
23 |
23 |
23 |
|
|
|||||||
2500 |
Mean |
16.6 |
21.2 |
24.1 |
24.8 |
26.8 |
26.7 |
SD |
2.4 |
2.1 |
2.5 |
2.2 |
3.0 |
2.4 |
|
n |
23 |
23 |
23 |
23 |
23 |
23 |
|
|
|||||||
5000 |
Mean |
14.0 |
19.7** |
23.3 |
24.4 |
26.5 |
26.4 |
SD |
2.8 |
3.1 |
2.5 |
1.9 |
2.4 |
2.7 |
|
n |
24 |
24 |
24 |
24 |
24 |
24 |
|
|
|||||||
7500 |
Mean |
11.0*** |
19.2** |
22.4** |
23.0 |
26.0 |
26.1 |
SD |
3.2 |
3.3 |
2.8 |
3.5 |
2.9 |
2.8 |
|
n |
24 |
24 |
24 |
24 |
24 |
24 |
Table 4. Group Mean Litter Data Values |
|||||
Dietary Concentration (ppm) |
|
Mean Male Foetal Weight (g) |
Mean Female Foetal Weight (g) |
Mean Foetal Weight (g) |
Mean Placental Weight (g) |
0 (Control) |
Mean |
4.012 |
3.826 |
3.922 |
0.640 |
SD |
0.272 |
0.233 |
0.244 |
0.080 |
|
n |
23 |
23 |
23 |
23 |
|
|
|||||
2500 |
Mean |
3.925 |
3.756 |
3.840 |
0.626 |
SD |
0.229 |
0.241 |
0.231 |
0.100 |
|
n |
23 |
23 |
23 |
23 |
|
|
|||||
5000 |
Mean |
3.952 |
3.742 |
3.855 |
0.694 |
SD |
0.304 |
0.308 |
0.289 |
0.144 |
|
n |
24 |
24 |
24 |
24 |
|
|
|||||
7500 |
Mean |
3.712** |
3.550** |
3.635** |
0.559** |
SD |
0.313 |
0.329 |
0.309 |
0.079 |
|
n |
24 |
24 |
24 |
24 |
Effect on developmental toxicity: via oral route
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 387.2 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
Effect on developmental toxicity: via inhalation route
- Endpoint conclusion:
- no study available
Effect on developmental toxicity: via dermal route
- Endpoint conclusion:
- no study available
Additional information
In a key pre-natal developmental toxicity study (Envigo Research Ltd., 2017c), the test material (Rosin, CAS# 8050-09-7) was administered by continuous dietary admixture to three groups each composed of twenty-four time mated Sprague-Dawley Crl:CD®(SD) IGS BR strain rats, between gestation days 3 and 19 (inclusive) at dietary concentrations of 2500, 5000, or 7500 ppm (equivalent to mean achieved dosages of 199.3, 387.2 or 561.1 mg/kg bw/day respectively). A further group of twenty-four time mated females was fed basal laboratory diet to serve as a control.
Clinical signs, body weight change, food and water consumptions were monitored during the study. All females were terminated on gestation day 20 and subjected to gross necropsy including examination of the uterine contents. The number of corpora lutea, number, position and type of implantation, placental weights, foetal weight, sex and external and internal macroscopic appearance were recorded. Half of the pups from each litter were examined for detailed skeletal development and the remainder were subjected to detailed visceral examination.
The oral administration of the test material to pregnant rats by continuous dietary exposure was associated with lower maternal body weight gain during gestation and an initial effect on food consumption at 7500 ppm and lower maternal body weight gain at 5000 ppm. No similar effects were apparent at 2500 ppm (equivalent to a mean achieved dosage of 199.3 mg/kg bw/day) which was considered to represent the No Observed Adverse Effect Level (NOAEL) for the pregnant female.
In-utero survival of the developing conceptus was unaffected by maternal exposure at 7500 ppm, although reduced foetal and placental weights indicated an adverse effect on foetal growth. The absence of any structural defects indicated that development per se was unaffected at this dietary exposure level. At 5000 or 2500 ppm no adverse treatment-related changes were detected in the offspring parameters measured or on embryofoetal development. The ‘No Observed Adverse Effect Level’ (NOAEL) for foetal developmental toxicity was therefore considered to be 5000 ppm (equivalent to a mean achieved dosage of 387.2 mg/kg bw/day).
The potential for Rosin (Tall oil rosin, CAS# 8050-09-7) has been evaluated in a reproductive/developmental toxicity study conducted according to OECD Guideline 422, in which the test material was administered daily in dietary mixtures at concentrations of 0, 2500 ppm, 5000 ppm, or 10000 ppm to male rats for 42 days and to female rats for 14 days prior to pairing, through the pairing and gestation periods until the F1 generation reached day 4 post-partum.
For developmental toxicity, the NOEL was established at 5000 ppm, based on slightly reduced body weight and body weight gain observed in pups during lactation in the 10000 ppm concentration group. Although the reduction was only minor and predominantly not statistically significant if compared to the current control, values at the high concentration level were lower if compared to the historical control background and therefore this observation was considered to be related to the treatment with the test item. The NOAEL for developmental toxicity was established at the concentration level of 10000 ppm, the highest concentration tested in the study (Harlan Laboratories Ltd., 2015a).
The potential for Rosin, hydrogenated (CAS# 65997-06-0) has been evaluated in a reproductive/developmental toxicity study conducted according to OECD Guideline 422, in which the test material was continuously administered in feed to rats (12/sex/concentration) at concentrations of 0, 1000, 3000, and 10000 ppm. The test material was administered to male rats for 43 days and to female rats for 14 days prior to pairing, through the pairing and gestation periods until the F1 generation reached day 4 post-partum. For developmental toxicity, the NOEL was established at the dose level of 3000 ppm, based on a slight retardation in pup body weights in the presence of adversely reduced food consumption and body weight in females in the high concentration group. No effects on development were observed during the study. The changes in pup body weights were only minor (not statistically significant if compared to the control group), and values in the high-dose group were close to the normal background range in this rat strain. The reduction in pup body weights represents a delayed growth rather than a developmental disturbance. This effect is commonly seen in the presence of maternal toxicity manifested as decreased food consumption associated with reduced body weights and it is considered to be secondary to the maternal toxicity. For these reasons, effects on pup body weights were considered not to be adverse and likely to be a secondary response. Therefore, the NOAEL for developmental toxicity was determined to be 10000 ppm, the highest dose level used in the study (Harlan Laboratories Ltd., 2015b).
The potential for Rosin, reaction products with formaldehyde has been evaluated in a reproductive/developmental toxicity study conducted according to OECD Guideline 422, in which the test material was administered daily in dietary mixtures at concentrations of: 0, 1000, 3000 and 10000 ppm to male rats for 43 days and to female rats for 14 days prior to pairing, through the pairing and gestation periods until the F1 generation reached day 4 post-partum. No unscheduled deaths were recorded during the study period. No clinical signs were recorded. Slight reductions in food consumption and water consumption and low body weight and body weight gain was recorded in males and females of group 4. The effect was likely due to the reduced palatability of the diet at the higher concentration. Slightly low body weights and reduced water consumption were noted in males of groups 2 and 3. Minimal hypertrophy of the zona glomerulosa were observed in the adrenal glands in males and females of groups 3 and 4. The pathogenesis was considered to be an adaptive process following stimulation of this system. Increased liver weights were recorded at necropsy in males and females of group 4 and these findings are suggestive of an adaptive response to mixed function oxidase induction and considered not to be adverse. The sperm motility, morphology and sperm count, estrus cycle, mating performance, fertility, duration of gestation, corpora lutea count, implantation rate, post-implantation and postnatal loss and litter size were not affected by treatment with the test material at any concentration. There were no test material-related findings in pups noted during the first litter check, the first 4 days post-partum or during the necropsy. Based on the result of the study, the NOAEL (No Observed Adverse Effect Level) for general toxicity was established at a concentration of 10000 ppm and the NOEL (No Observed Effect Level) was established at a concentration of 1000 ppm.The NOAEL and NOEL for reproduction/ developmental toxicity were established at a concentration of 10000 ppm, the highest concentration used in the study (Harlan Laboratories Ltd., 2015c).
The potential for Rosin (Gum Rosin; CAS# 8050-09-7) has been evaluated in a reproductive/developmental toxicity study conducted according to OECD Guideline 422, in which the test material was administered to rats (12/sex/dose) in dietary mixtures at concentrations of 0, 2500, 5000, and 10000 ppm for a period of 50 days for male rats and to female rats for 14 days prior to pairing, through the pairing and gestation periods until the F1 generation reached day 4 post-partum (at least 36 days, up to 53 days). The NOEL and the NOAEL for developmental toxicity were established at 5000 ppm, based on mortality and body weight effects observed at the 10000 ppm concentration level (Harlan Laboratories Ltd., 2014a).
The potential for Rosin, oligomers (CAS# 65997-05-9) has been evaluated in a reproductive/developmental toxicity study conducted according to OECD Guideline 422, in which the test material was administered to rats (12/sex/concentration) in dietary mixtures at concentrations of 0, 3000, 7500 and 15000 ppm. The test material was continuously administered to male rats for 43 days and to female rats for 14 days prior to pairing, through the pairing and gestation periods until the F1 generation reached day 4 post-partum (up to 55 days). The NOEL and the NOAEL for developmental toxicity was determined to be 3000 ppm, based on effects on pup body weight at concentrations of 7500 and 15000 ppm (Harlan Laboratories Ltd., 2014b).
The potential for Gum Rosin (Rosin) to cause developmental toxicity has been evaluated in a reproductive and developmental toxicity screening study conducted according to OECD Guideline 421 in which male and female Sprague Dawley rats were exposed to up to 10000 ppm test substance in the diet during premating, mating, gestation and lactation for a total of 30 exposure days for males and 41-45 exposure days for females study (Inveresk Research, 2003a). At 10000 ppm in the diet, there was a decrease in weight gain or weight loss over the first few weeks of treatment. Decreased weight gain was more severe in females, occurring during the first week on study. After this period, mean weight gain was similar to controls. Pregnant female weight gain was slightly decreased during the first half of gestation. Food consumption was significantly reduced in the 10000 ppm animals for the first 2 weeks of treatment, for both sexes. Food consumption was also slightly reduced throughout gestation and lactation. Consumption at the two lower levels was similar to that of controls. At 10000 ppm, test substance intake in the first week of treatment was lower than the second week for both sexes. There was also a decreased intake in the first week of gestation at this dietary level. For dams, no test material-related effects were noted on mean gestation length or the process of parturition at any exposure concentration. Mean litter and pup weights were slightly reduced for the 10000 ppm dams. There were no obvious external malformations noted in the pups at any of the dose levels in this study. The NOAEL was 3000 ppm, equivalent to a received dose of 288 mg/kg bw/d from GD0 to PND4.
Justification for classification or non-classification
Not classified for reproductive or developmental toxicity according to EU Classification, Labelling and Packaging of Substances and Mixtures (CLP) Regulation (EC) No. 1272/2008 or UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS).
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.